Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are comparing different sequences of therapy for people with newly diagnosed multiple myeloma. All participants will get cilta-cel CAR T-cell therapy, a form of immunotherapy made from your own white blood cells.
The purpose of this study is to find the highest dose of the investigational drug glofitamab that can be given safely alone or with obinutuzumab in patients with non-Hodgkin lymphoma that came back or continued to grow despite treatment. Glofitamab is a "bispecific antibody" that binds to two different proteins: one found on the surface of cancer cells and one found on the surface of immune cells. Researchers think that glofitamab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Both drugs are given intravenously (by vein).
Peritoneal mesothelioma is a cancer of the inner lining of the abdomen (belly). The people in this study will be having surgery to take out as much of the cancer as possible. They will also receive heated chemotherapy given directly into the abdomen to kill any remaining cancer cells.
Researchers want to see if adding IMNN-001 to standard treatment works well against advanced gynecologic cancers. The people in this study have newly diagnosed ovarian, fallopian tube, or primary peritoneal cancers.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Inotuzumab ozogamicin is a drug used to treat adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite prior therapy. In this study, researchers are evaluating its use in children and young adults with recurrent or persistent B-cell ALL.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this study is to see if the drug pasireotide works well to treat prolactinomas. Prolactinomas are noncancerous pituitary gland tumors that make too much prolactin. Prolactin is a hormone that causes the body to make less estrogen and testosterone (sex hormones).
The purpose of this study is to find the highest dose of the investigational drug codrituzumab that can be given safely in children and young adults with solid tumors that came back or continued to grow despite treatment. Codrituzumab works by targeting a protein called GPC3, which can drive the growth of some forms of cancer that affect children and young adults. It is given intravenously (by vein).
People with early-stage breast cancer who undergo lumpectomy have traditionally also received radiation therapy and hormonal (endocrine) therapy to reduce their risk of breast cancer recurrence. Doctors want to know if some patients with low-risk early-stage breast cancer can forgo radiation therapy (which takes several weeks and has side effects) and do as well if they receive only hormonal therapy after lumpectomy.
